Your browser doesn't support javascript.
loading
Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.
Zhang, H; Hylander, B L; LeVea, C; Repasky, E A; Straubinger, R M; Adjei, A A; Ma, W W.
Afiliación
  • Zhang H; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA.
  • Hylander BL; Department of Immunity, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA.
  • LeVea C; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA.
  • Repasky EA; Department of Immunity, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA.
  • Straubinger RM; Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, USA.
  • Adjei AA; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA.
  • Ma WW; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton streets, Buffalo, NY 14263, USA.
Br J Cancer ; 110(2): 320-9, 2014 Jan 21.
Article en En | MEDLINE | ID: mdl-24327018

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos Tipo de estudio: Prognostic_studies Idioma: En Revista: Br J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos Tipo de estudio: Prognostic_studies Idioma: En Revista: Br J Cancer Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos